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Abstract
Background: Ghrelin, an orexigenic gut hormone secreted primarily from the stomach, is involved in energy homeostasis.
However, little data is available regarding its response to energy surplus and the development of human obesity.
Objective: The present study investigated the response of circulating acylated ghrelin to a 7-day positive energy challenge.
Design: A total of 68 healthy young men were overfed 70% more calories than required, for 1-week. Subjects were classified
based on percent body fat (measured by dual-energy X-ray absorptiometry) as normal weight, overweight, and obese.
Serum acylated ghrelin concentration was measured before and after the positive energy challenge. Additionally, the
relationship between acylated ghrelin and obesity-related phenotypes including weight, body mass index, percent body fat,
cholesterol, HDL-c, LDL-c, glucose, insulin and homeostasis model assessment of insulin resistance and b-cell function at
baseline and change due to overfeeding, were assessed.
Results: Contrary to our expectations, serum acylated ghrelin was significantly increased in response to overfeeding and the
increase was independent of obesity status. There was no significant difference in fasting acylated ghrelin between normal
weight, overweight, and obese men at baseline. Acylated ghrelin was negatively correlated with weight and BMI for normal
weight and with BMI in overweight men. Also ghrelin was correlated with change in weight and BMI in overweight
(negative relationship) and obese (positive relationship) groups.
Conclusion: Our results showed that circulating acylated ghrelin was increased after a 7-day positive energy challenge
regardless of adiposity status. However, acylated ghrelin was correlated with change in weight and BMI in opposing
directions, in overweight and obese subjects respectively, thus dependent on obesity status.
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Introduction
Although it has been well-established that appetite is controlled
through complex mechanisms mainly in the central nervous
system (CNS), appetite-regulating hormones secreted from the
periphery, including the gastrointestinal tract (gut), communicate
with the CNS to play an important role in energy homeostasis
[1–3]. Ghrelin, an endogenous ligand of the growth hormone
secretagogue receptor (GHS-R), is the only known orexigenic gut
hormone, which increases appetite and food intake [4–6].
Ghrelin is found in both the gastrointestinal tract and
hypothalamus, though it is primarily synthesized and released
from X/A like cells of the gastric mucosa of the stomach [4,7–9].
Both acylated and non-acylated forms of ghrelin exist, however
the active form is n-octanoylated on the third amino acid (serine)
residue [4,10,11]. Ghrelin is thought to be a meal initiator:
concentration rises prior to feeding, and continually decreases to
a minimum one-hour after the meal [12,13]. The postprandial
suppression of circulating ghrelin is proportional to the caloric
content of the consumed meal [14].
Many studies have investigated ghrelin’s role in the regulation of
appetite and energy homeostasis. Administration of ghrelin in both
rats and humans has been shown to increase appetite and food
intake [6,15–18]. However in humans, most studies have found a
negative relationship between ghrelin and adiposity: higher
circulating ghrelin concentrations in lean individuals as compared
to obese [19–24]. In contrast, other studies have found positive
relationships between acylated ghrelin concentrations and markers
of adiposity [25] or a negative relationship with BMI and no
PLOS ONE | www.plosone.org 1 September 2012 | Volume 7 | Issue 9 | e45748
relationship to body fat [26]. Additionally, a growing body of
evidence shows that ghrelin might have a role in insulin resistance
and development of type 2 diabetes. Animal studies have shown
that ghrelin can inhibit insulin secretion, but increases glucagon
secretion from pancreatic islet cells [27]. Moreover human studies
reveal that patients with insulin resistance have lower ghrelin
concentrations compared with insulin-sensitive patients [28].
Circulating ghrelin concentration seems to be influenced
through dietary regulation and specific nutrient intakes. For
example, a high-fat meal has been shown to decrease circulating
ghrelin concentration in humans [29,30]. Moreover, our labora-
tory and others have revealed changes in nutritional status, such as
overfeeding influence adipokine and gut hormone concentrations
[31,32], adipose tissue metabolism [33,34] and genomic expres-
sion [35]. Intervention based studies, observing nutritional
regulation via a positive energy challenge, are also important in
understanding the role of ghrelin in the development of human
obesity where energy surplus is the major driving factor [36–40].
Currently, data is missing in this aspect.
Our current research goal was to investigate the potential role of
acylated ghrelin on the development of human obesity by
examining: 1) the response of fasting serum acylated ghrelin
concentrations in normal weight, overweight, and obese males to
short-term overfeeding; 2) fasting serum acylated ghrelin concen-
trations in each adiposity group before and after overfeeding; and
3) the relationships of fasting serum acylated ghrelin concentra-
tions with fasting glucose and insulin concentrations, blood lipids,
and insulin resistance state, before and after overfeeding.
Materials and Methods
Ethics Statement
All participants provided informed and written consent. The
current study received ethical approval from the Human
Investigations Committee for the Faculty of Medicine, Memorial
University of Newfoundland, St. John’s, Newfoundland and
Labrador, Canada.
Subjects
A total of 68 young males from the Canadian province of
Newfoundland and Labrador were recruited to study the effects of
an acute positive energy balance on metabolism and various
endocrine factors. Participation criteria included: 1) age 19–29
years; 2) at least of 3rd-generation Newfoundland descent; 3) no
serious cardiovascular, metabolic, or endocrine diseases; 4) no
medications intended for lipid metabolism change; and 5) a stable
6-month reported body weight value (62.5 kg). Recruited subjects
were asked to refrain from 1) consuming alcoholic or additional
calorie-containing beverages and from 2) taking any drugs or
medication, throughout the duration of the research study.
Serum Measurements
Blood samples were collected from all subjects both before and
after completion of the positive energy challenge (explained
below). Serum was prepared from clotted samples collected after a
12 hour fast which were stored at 280uC until time of further
analysis. Serum acylated ghrelin concentrations were measured in
duplicate with enzymeimmunosorbent assay (EIA) kits (Bertin
Pharma; Montigny le Bretonneux, France). Acylated ghrelin
analyses were performed on ice. The concentrations of serum
total cholesterol, high-density lipoprotein (HDL) cholesterol,
triacylglycerols (TG), and glucose were analyzed using Synchron
reagents by an Lx20 clinical chemistry analyzer (Beckman Coulter
Inc., CA, USA). Low-density lipoprotein (LDL) cholesterol was
calculated by the Friedwald equation: total cholesterol – HDL –
TG/2.2 (which is a reliable estimate in the absence of severe
hypertriglyceridemia .4.6 mmol/L). Serum insulin was evaluated
using an Immulite 2500 immunoassay analyzer (Siemens, Los
Angeles, CA). Insulin resistance and pancreatic b-cell function
were assessed using the homeostasis model assessment (HOMA).
Insulin resistance was quantified using HOMA-IR [insulin (mU/L)
6 glucose (mmol/L)/22.5)] while b-cell function was measured
using HOMA-b [206 insulin (mU/L/(glucose (mmol/L)-3.5)].
Body Composition Assessment
Dual-energy X-ray absorptiometry (DXA Lunar Prodigy; GE
Medical Systems, Madison, WI) was used to measure body
composition (lean tissue, body fat, and bone mineral composition).
Following a method previously described by us [41] the
participant was scanned in a supine position after a 12-hour fast
and the following parameters were determined from the DXA
scan: total percent body fat (%BF), percent trunk fat (%TF),
percent android fat (%AF), and percent gynoid fat (%GF). All
measurements were performed before overfeeding and on the day
after overfeeding.
Anthropometric Measurements
Measurements of body weight, height, waist circumference, and
hip circumference were performed after a12-hour fasting period.
Body weight was measured to the nearest 0.1 kilogram on a
platform manual scale balance (Health O Meter, Bridgeview, IL)
with subjects wearing a standardized hospital gown. A fixed
stadiometer was used to measure height to the nearest 0.1
centimeters (shoes removed). A flexible measuring tape was
employed to measure waist circumference to the nearest 0.1
centimeters at the level of the umbilicus. The same procedure was
used to measure hip circumference at the level of largest
circumference between the waist and thighs. Body mass index
(BMI) was calculated by dividing participants’ weight in kilograms
by the square of height in centimeters [(weight-kg)/(height-m)2].
Overfeeding Protocol
Participants enrolled into a 7-day positive energy challenge and
were required to consume 70% more calories than their normal
food intake. Throughout the challenge period, subjects followed a
diet consisting of 15% protein, 35% fat, and 50% carbohydrates,
thus mimicking typical North American dietary patterns. A 7-day
positive energy challenge was selected to ensure that metabolic
changes were induced throughout its duration. Individual energy
requirements were recorded and estimated before commencing
the overfeeding protocol by the use of three 24-hour recalls and a
30-day dietary inventory. For one week at time 0900, 1200, and
1700, participants were offered meals of which caloric and
macronutrient content was assessed using FOOD PROCESSOR
SQL software (version 9.5.0.0; ESHA Research, Salem, OR). The
average baseline energy intake before and during overfeeding were
2969 kcal and 5471 kcal, respectively. A detailed overfeeding
protocol has been described in our previously published papers
[33,34].
Statistical Analysis
Data are presented as means 6 SE unless otherwise stated.
Prior to analysis, data that showed a skewed distribution was
logarithmically transformed to approximate a normal distribution.
Concentration data for serum acylated ghrelin, triacylglycerols,
insulin, and HOMA-IR and HOMA-b, all at baseline, after, and
change during overfeeding were log transformed prior to analysis.
Ghrelin and Overfeeding
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Using criteria suggested by Bray [42] subjects were classified as
either normal weight, overweight or obese based upon %BF (8–
20.9, 21–25.9 and $26%, respectively). Subjects were also
classified using the World Health Organization BMI-based
classification (BMIs of #24.9, 25.0–29.9, and $30 kg/m2 for
normal weight, overweight, and obese respectively). Because of its
more accurate classification of obesity status, Bray Criteria was
used for subsequent analyses.
Using a two-factor analysis of variance (ANOVA) with repeated
measures before and after overfeeding, differences in physical and
biochemical variables in response to overfeeding were assessed
between the three groups. One-factor analysis of variance was
used to compare baseline values between the three adiposity
groups. Variables which showed a significant overfeeding-adipos-
ity interaction underwent within-group analysis of the response to
overfeeding using a paired t-test. In both one factor and two-factor
ANOVA analyses, Bonferroni post hoc tests were employed.
Initial Pearson’s correlation analyses were performed to assess
relationships between fasting acylated ghrelin concentration and
physical/biochemical variables of interest. Next we performed
three correlation analyses: 1) baseline acylated ghrelin concentra-
tion was compared with all variables at baseline and 2) baseline
acylated ghrelin concentration was compared with changes in all
variables in response to overfeeding thus examining if baseline
acylated ghrelin could predict the changes in related physical and
biochemical markers. All statistical analyses were completed using
SPSS, version 19.0 (SPSS Inc, Chicago) in which: 1) all tests were
two-sided; and 2) a P value ,0.05 was deemed statistically
significant.
Results
Descriptive Statistics
Basal physical and biochemical characteristics of subjects are
shown in Table 1. Differences in body composition glucose, and
lipid metabolism between normal-weight, overweight, and obese
(based on %BF) young healthy men were previously described by
us [31,33–35].
Baseline fasting acylated ghrelin concentrations (mean 6 S.E.)
for normal weight, overweight, and obese individuals were
222.19641.60, 274.91692.4, and 352.036112.4 ng/L, respec-
tively. There was no statistically significant difference between
adiposity groups for acylated ghrelin concentration at baseline.
Similar results were obtained when participants were divided into
normal weight, overweight and obese groups based on the World
Health Organization’s BMI classification (data not shown).
Changes in body composition and phenotypes of glycemic
control and lipid metabolism in response to the 7-day overfeeding
challenge are also described in Table 1. Within all adiposity
groups, the positive energy challenge increased body composition,
serum lipids, insulin resistance, and pancreatic beta cell function,
which was previously described by us [31,33–35].
In response to the 7-day overfeeding challenge, circulating
acylated ghrelin concentration significantly increased by
62.14 ng/L in the entire cohort (P = 0.042). However, no
adiposity-overfeeding interaction was present; the response of
acylated ghrelin to overfeeding was not significantly different
between normal weight, overweight, and obese groups (P= 0.523).
Correlations of Acylated Ghrelin with Adiposity and
Phenotypes of Glucose and Lipid Metabolism
Partial correlation analyses, controlling for age, were used to
assess the relationships between baseline fasting acylated ghrelin
concentration and baseline phenotypes of adiposity, and serum
glucose and lipid concentrations (Table 2). For normal weight
subjects, acylated ghrelin was negatively correlated with weight
and BMI (P,0.05). Furthermore, fasting glucose concentration
was positively correlated with acylated ghrelin concentrations. The
significant negative correlation between acylated ghrelin and BMI
was also observed in overweight subjects, but not in obese subjects.
LDL cholesterol was negatively correlated with acylated ghrelin
concentration only in obese subjects.
Additionally, partial correlation analyses examining the rela-
tionship between baseline acylated ghrelin concentration and
changes in variables after the overfeeding period were used to
examine if acylated ghrelin concentration could predict variable
change under a positive energy challenge (Table 3). Significant
negative relationships were found for the overweight group,
between baseline acylated ghrelin concentration and change in
body weight and BMI. However, the relationship between baseline
acylated ghrelin and change in body weight and BMI, were
positive for obese subjects.
Acylated Ghrelin Tertiles: Correlations of Acylated Ghrelin
with Phenotypes of Adiposity and Concentrations of
Glucose and Lipids
We repeated all of the above analyses after participants were
divided into acylated ghrelin tertile subgroups (low, medium, and
high ghrelin; data not shown). Only one baseline correlation
existed within the analysis. For the high ghrelin subgroup, baseline
acylated ghrelin was positively correlated with baseline fasting
triacylglycerols. No significant relationships were found when
partial correlation analyses were performed examining baseline
acylated ghrelin concentrations and changes in the aforemen-
tioned variables.
Discussion
The most important finding from the present study was the
discovery of the significant increase in serum acylated ghrelin
concentration after the 7-day positive energy challenge. Conven-
tional knowledge would lead us to expect that to counteract a
positive energy balance (thus limiting caloric intake) during
overfeeding, secretion of ghrelin would be diminished to decrease
appetite. However, the results from our study was surprisingly the
opposite; acylated ghrelin concentration significantly increased
after the 7-day overfeeding challenge regardless of adiposity status.
Pathologically high circulating concentrations of ghrelin are
known to occur in the inherited disease of Prader-Willi Syndrome,
which is characterized by uncontrollable appetite [43–45], but also
in cases of anorexia nervosa, where there is little appetite [46,47].
At the present time, results are not clear based on limited studies
examining the responsiveness of ghrelin to a positive energy
challenge. Moreover, the few available studies with positive energy
challenge interventions differ in many aspects including length of
overfeeding, macronutrient composition, amount of food con-
sumed above daily caloric requirements, and also the physical and
demographic characteristics of the study participants. Hagobian
et al. overfed 9 healthy subjects (6 men and 3 women) 25% more
calories than required for weight maintenance for 3 days, retaining
a macronutrient composition of 56% carbohydrate, 29% fat, and
15% protein, and found no significant change in circulating
ghrelin concentration [38]. Votruba et al. overfed 69 non-diabetic,
mainly obese individuals (40 men and 29 women) 60% more
calories than required at baseline from a ‘‘vending machine diet’’
over a 3-day period [37]. Circulating ghrelin concentration did not
change through the 3-day duration. A 5-day high fat (60% fat,
32.5% carbohydrates and 7.5% protein) overfeeding study (50%
Ghrelin and Overfeeding
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more calories than required) found a non-significant increase in
circulating ghrelin in a cohort of 26 healthy young men [36].
Robertson et al. overfed 6 healthy lean male subjects by
,692.7 kcal/day with a high fat diet ranging from 29–45%
calories from fat. This study detected no significant change in
fasting ghrelin, however, postprandial ghrelin was suppressed to a
greater extent following the oral fat tolerance test [39]. Finally, a
long-term overfeeding study of 100-day in which twelve pairs of
identical twins consumed an excess of 84,000 kilocalories (50%
carbohydrates, 35% fat, and 15% protein) revealed a non-
significant decrease in plasma ghrelin concentration [40]. Our
current study using a typical North American diet (15% protein,
35% fat, and 50% carbohydrates) and a homogenous large sample
size consisting of only young male university students, detected a
significant increase in circulating acylated ghrelin after 7 days of
overfeeding. The reason for the increased acylated ghrelin
Table 2. Partial correlations of baseline variables related to baseline fasting serum ghrelin concentrationa,b.
All Subjects (n =68) Normal Weight (n =26) Overweight (n=14) Obese (n =28)
r P r P r P r P
Weight (kg) 20.012 NS 20.431 0.032 20.234 NS 0.089 NS
BMI (kg/m2) 20.037 NS 20.404 0.045 20.667 0.013 0.067 NS
Percent body fat 20.007 NS 20.226 NS 20.440 NS 20.086 NS
Percent trunk fat 20.034 NS 20.277 NS 20.425 NS 20.130 NS
Percent android fat 20.035 NS 20.169 NS 20.548 NS 20.112 NS
Percent gynoid fat 0.070 NS 20.096 NS 0.137 NS 0.122 NS
Total cholesterol 20.138 NS 0.392 NS 20.370 NS 20.353 NS
HDL cholesterol 20.148 NS 0.274 NS 20.438 NS 20.290 NS
LDL cholesterol 20.178 NS 0.292 NS 20.293 NS 20.436 0.023
Triacylglycerols 0.145 NS 0.213 NS 20.073 NS 0.172 NS
Glucose 20.015 NS 0.473 0.017 20.140 NS 20.185 NS
Insulin 0.069 NS 0.187 NS 0.192 NS 20.071 NS
HOMA-IR 0.061 NS 0.231 NS 0.152 NS 20.092 NS
HOMA-b 0.097 NS 20.034 NS 0.384 NS 0.036 NS
aPartial correlations controlled for age were used to screen for variables related to fasting ghrelin (P,0.05) (IBM SPSS Statistics 19).
bHomeostasis model assessment of insulin resistance (HOMA-IR) and of B cell function (HOMA-b); NS, non-significant. Subjects were classifed based on adiposity
recommendations by Bray as normal weight (8–20.9%), overweight (21–25.9%), or obese (.26%).
doi:10.1371/journal.pone.0045748.t002
Table 3. Partial correlations of change in variables related to baseline fasting serum ghrelin concentrationa,b.
All Subjects (n =68) Normal Weight (n =26) Overweight (n=14) Obese (n =28)
r P r P r P r P
Weight (kg) 0.217 NS 0.208 NS 20.590 0.034 0.618 0.001
BMI (kg/m2) 0.218 NS 0.227 NS 20.599 0.031 0.616 0.001
Percent body fat 20.017 NS 0.297 NS 20.170 NS 20.145 NS
Percent trunk fat 20.042 NS 0.235 NS 20.086 NS 20.159 NS
Percent android fat 0.084 NS 0.246 NS 0.159 NS 20.080 NS
Percent gynoid fat 20.047 NS 0.017 NS 20.298 NS 0.098 NS
Total cholesterol 0.022 NS 20.056 NS 20.043 NS 0.124 NS
HDL cholesterol 0.006 NS 20.167 NS 20.125 NS 0.185 NS
LDL cholesterol 0.041 NS 20.134 NS 0.026 NS 0.202 NS
Triacylglycerols 20.016 NS 0.233 NS 20.108 NS 20.103 NS
Glucose 20.026 NS 20.124 NS 20.169 NS 0.106 NS
Insulin 20.082 NS 0.044 NS 20.178 NS 20.135 NS
HOMA-IR 20.080 NS 0.013 NS 20.206 NS 20.086 NS
HOMA-b 20.061 NS 0.155 NS 20.012 NS 20.343 NS
aPartial correlations controlled for age were used to screen for variables related to fasting ghrelin (P,0.05) (IBM SPSS Statistics 19).
bHomeostasis model assessment of insulin resistance (HOMA-IR) and of B cell function (HOMA-b); NS, non-significant. Subjects were classifed based on adiposity
recommendations by Bray as normal weight (8–20.9%), overweight (21–25.9%), or obese (.26%).
doi:10.1371/journal.pone.0045748.t003
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concentration after the positive energy challenge is not clear. In
animal studies, the infusion of ghrelin has been shown to result in
inhibition of beta-cell function and insulin secretion, but also an
increase in insulin sensitivity [27,48,49]. Additionally in cross-
sectional human studies, fasting ghrelin is negatively associated
with insulin resistance [50]. It is therefore possible that the
increased ghrelin secretion due to overfeeding was a counteractive
response to the rising insulin resistance after the 7-day overfeeding,
though this is purely speculative as multiple factors must be in
play. However, the role of this increased response by ghrelin in
long-term energy homeostasis, including the development of
human obesity, warrants further study.
Although it has been reported that circulating ghrelin is higher
in lean individuals than overweight and obese individuals [19–24],
our cohort showed no significant difference in circulating acylated
ghrelin among the three adiposity groups. However, when subjects
were divided according to adiposity status, BMI was negatively
correlated with acylated ghrelin concentration in both normal
weight and overweight subjects. This is in line with the observation
that ghrelin may help maintain healthy body weight and BMI.
The reason why such correlation was not observed in obese
subjects is unclear. It is possible that the normal hormonal
mechanism of ghrelin was dysfunctional in the obese state, as seen
for many other hormones [51,52]. This was further demonstrated
by the differences in correlations found in overweight and obese
subjects, between baseline acylated ghrelin and change in weight
and BMI. Overweight subjects showed a negative relationship,
while obese subjects showed a positive relationship, between
fasting baseline acylated ghrelin and change in body weight and
BMI. Thus higher baseline acylated ghrelin predicts low weight
gain and BMI in the overweight group, but the opposite is true of
the obese group. This may predispose to further weight gain in
obese people.
Additionally, we sought to examine the association of acylated
ghrelin with serum indices of lipid and glucose metabolism. The
associations between ghrelin and circulating lipids/glucose seem to
be affected by obesity status. We observed that only baseline
acylated ghrelin concentration was positively associated with
fasting glucose concentration in normal weight subjects. Addition-
ally in obese subjects, acylated ghrelin was negatively related to
circulating LDL cholesterol concentration. Why these relation-
ships were found in specific adiposity groups is unknown.
Evidently, more studies are warranted to further grasp the
physiological association of ghrelin with glucose and lipid
metabolism.
The present study is not without limitations. We only studied
young men of the same ethnicity thus limiting its potential
application to other ethnic, age, or female groups. Future large
scale studies including females and a wider age range are needed
to further understand the response of ghrelin to a positive energy
challenge. Additionally, it must be noted that ghrelin concentra-
tions are affected by meals [53]. However in our investigation, the
relationship between ghrelin and aforementioned physiological
measurements were completed in a fasting state. Data of area
under the curve after a standardized meal may provide additional
useful information.
In summary, the response of acylated ghrelin to a short-term
positive energy challenge was studied in 68 young healthy men.
Serum acylated ghrelin was measured before and after a 7-day
overfeeding challenge in 68 young men. Surprisingly, fasting
ghrelin concentration was significantly increased in response to the
positive energy challenge in the entire cohort. Based on our
finding and the literature, we hypothesize that this increase may
counteract the rising insulin resistance. At baseline, there were no
significant differences in circulating acylated ghrelin concentration
between normal weight, overweight, and obese men. However
negative correlations were observed between ghrelin and BMI, in
normal weight and overweight subjects. The baseline acylated
ghrelin concentration correlated with change in weight and BMI
in opposite directions in overweight and obese subjects. Thus
future studies are warranted to understand the mechanistic
pathway of ghrelin to further elucidate its role in energy
homeostasis and human obesity.
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